However, a few clinical characteristics, including tumor location, CEA level, and tumor maximum diameter, were significantly different between patients with stage I-II and III-IV PDAC in the training cohort (Table 1); all of these clinical characteristics were included in the clinical predictive model. Here, CEACAM5 is linked to neoplasm.